National and Kapodistrian University of Athens
Ανταγωνιστές μπομπεσίνης επισημασμένοι με 99mTc για εφαρμογή στη διαγνωστική ογκολογία
Abstract
dc:descriptionIn recent years important progress has been made in diagnostic oncology byapplying specialized site-specific radiolabeled compounds. Research is mainlyfocusing on the development of radiolabeled peptides because they offer severaladvantages such as rapid biokinetics, high penetration capacity into cancer tissuedue to their low molecular weight and low antigenicity. Radiopeptides interactselectively with target-biomolecules (peptide receptors) which are overexpressed onthe surface of cancer cells. Therefore, they act as transporters of diagnostic ortherapeutic radionuclides to the target (malignant lesions), providing the possibility ofhigh contrast imaging or cell damage.Bombesin is a 14-amino acid peptide with high affinity for gastrin releasingpeptide receptors (GRP-Rs) which are overxpressed in a variety of human tumorsincluding prostate and breast cancers.In the present thesis, the synthesis and preclinical evaluation of novelbombesin antagonists radiolabeled with 99mTc for potential application in targeteddiagnostic imaging of GRP-R+tumors, is described.Synthesis of the new peptides was based on the bombesin antagonist peptide[D-Phe6,Leu-NHEt13]BBN(6-13) and modifications occurred at the N-terminus, Cterminusand/or at the peptide chain of this antagonist.The radionuclide of choice was 99mTc because of its ideal nuclear properties. Abifunctional tetraamine precursor H2NCH2CH2NH(CH2)3NHCH2CH2NH2 (2,3,2-tet)was used for the stable binding of 99mTc. Incorporation of 99mTc by the tetraamine unitwas almost quantitative as it was confirmed by chromatographic analysis.Binding affinity of the new analogs for the GRP-R was studied withcompetition binding experiments in PC-3 cell membranes and it was high, evenhigher than the peptide of reference [Tyr4]BBN. These results show the favorableeffect of the tetraamine complex at the N-terminus of the new peptides. Also thebinding affinity of the radiolabeled peptide was studied for [99gTc/99mTc]Demobesin 8by saturation binding experiments in whole PC-3 cells and it was significantly high (Kd= 0.24±0.03 nM) indicating that the presence of the [TcV(O)2N4)]+ complex at the Nterminusof the peptide affects positively the binding affinity to GRP-R.Metabolic studies for [99mTc]Demobesin 8 were conducted in mouse plasma,kidney homogenates and urine. [99mTc]Demobesin 8 survived long enough inmouse plasma, whereas in kidney homogenates it rapidly degraded in hydrophilic metabolites and it is finally excreted into urine. HPLC analysis in urine that werecollected 30 min after the intravenous injection of the radiopeptide showed fulldegradation in the kidneys.Biodistribution studies in healthy and pathological animal models afterintravenous injection of the radiolabeled peptides confirmed the in vitro results. Theradioactivity rapidly cleared from the blood and background tissues and it wasexcreted mainly via kidneys and the urinary system.As it was mentioned before the main route of excretion of [99mTc]Demobesin 8is via the kidneys and the urinary system and not through the hepatobiliary systemdue to high hydrophilicity. This is expected to lead in rapid excretion from backgroundtissues and hence a possible better imaging of GRP-R positive tumors. Also higheruptake in organs that expressing GRP-R such as pancreas was observed for[99mTc]Demobesin 8. The process was GRP-R mediated, as shown by in vivoreceptor blockade by co-injection of excess of [Tyr4]BBN with each radiopeptide. InSCID mice bearing human PC-3 xenografts expressing the human GRP-R,[99mTc]Demobesin 8 achieved the higher uptake in tumor.In comparison with other radiolabeled bombesin antagonists, which are knownin the literature, [99mTc]Demobesin 8 showed the highest binding affinity for GRP-Rand also in vivo the highest tumor uptake. Moreover compared with agonistradiopeptides such as [99mTc]Demobesin 3-6 showed the more effective targeting ofGRP-R by antagonist peptides.In conclusion, this thesis successfully led in the development of new 99mTcradiolabeledbombesin antagonists for diagnostic imaging of GRP-R positive tumorsin human. This preclinical evaluation showed as the radiopeptide of choice[99mTc]Demobesin 8 because satisfied important criteria and combined a variety offavorable properties for successful application in the targeted diagnostic imaging ofGRP-R positive tumors such as favorable pharmacokinetics, metabolic stability aswell as rapid and high in vivo GRP-R targeting which can led to satisfactory tumorimages
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2012
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Charalambidis, David
- Χαραλαμπίδης, Δαυίδ
Subjects
dc:subject × 11Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/36264